Are PCSK9 inhibitors preferable to statins in patients with stroke risk?
A meta-analysis links statins to an increased risk of haemorrhagic stroke in a dose-dependent manner
Statins are associated with an increased risk of haemorrhagic stroke while proprotein convertase subtilisin/kexin type 9 inhibitors are not, say researchers who have pooled the evidence from randomised controlled trials.
Although the absolute risk of haemorrhagic stroke with statins is low, the US investigators suggest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors might be preferable for lipid lowering in patients at increased risk.
